anticoagulation. 7.3 allopurinol the concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. it is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients. 7.4 oral contraceptives amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives. 7.5 other antibacterials chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. this has been demonstrated in vitro ; however, the clinical significance of this interaction is notwell documented. 7.6 effects on laboratory tests high urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using clinitest ® (manufactured by miles, inc.), benedict’s solution, or fehling’s solution. since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions [such as clinistix ® (manufactured by bayer corporation)] be used. following administration of ampicillin or amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.

urinary tract, skin and skin structure, and lower respiratory tract. ( 1.1 – 1.5 ) • in combination for treatment of h. pylori infection and duodenal ulcer disease. ( 1.6 , 1.7 ) 1.1 infections of the ear, nose, and throat - due to streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . 1.2 infections of the genitourinary tract - due to escherichia coli, proteus mirabilis , or enterococcus faecalis . 1.3 infections of the skin and skin structure - due to streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli . 1.4 infections of the lower respiratory tract - due to streptococcus spp. (α- and β-hemolytic isolates only), s. pneumoniae, staphylococcus spp., or h. influenzae . 1.5 gonorrhea, acute uncomplicated (ano-genital and urethral infections in males and females) - due to neisseria gonorrhoeae . because of high rates of amoxicillin resistance, amoxicillin powder for oral suspension, usp is not recommended for empiric treatment of gonorrhea. amoxicillin powder for oral suspension, usp use should be limited to situations where n. gonorrhoeae isolates are known to be susceptible to amoxicillin. 1.6 triple therapy for helicobacter pylori with clarithromycin and lansoprazole: amoxicillin powder for oral suspension, usp, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate h. pylori . eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.7 dual therapy for h. pylori with lansoprazole: amoxicillin powder for oral suspension, usp, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected . (see the clarithromycin package insert, microbiology.) eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

osporins. before initiating therapy with amoxicillin, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. 5.2 clostridium difficile associated diarrhea clostridium difficile associated diarrhea (cdad) has been reported with use of nearly all antibacterial agents, including amoxicillin, and may range in severity from mild diarrhea to fatal colitis. treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of c. difficile. c. difficile produces toxins a and b which contribute to the development of cdad. hypertoxin-producing strains of c. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. cdad must be considered in all patients who present with diarrhea following antibacterial use. careful medical history is necessary since cdad has been reported to occur over 2 months after the administration of antibacterial agents. if cdad is suspected or confirmed, ongoing antibiotic use not directed against c. difficile may need to be discontinued. appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of c. difficile , and surgical evaluation should be instituted as clinically indicated. 5.3 potential for microbial overgrowth or bacterial resistance the possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. if superinfections occur, amoxicillin should be discontinued and appropriate therapy instituted. prescribing amoxicillin either in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient, and increases the risk of the development of drug-resistant bacteria. 5.4 use in patients with mononucleosis a high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash. thus amoxicillin should not be administered to patients with mononucleosis. 5.5 phenylketonurics the oral suspensions of amoxicillin do not contain phenylalanine and can be used by phenylketonurics.

he time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. it is recommended that there be at least 10 days’ treatment for any infection caused by streptococcus pyogenes to prevent the occurrence of acute rheumatic fever. in some infections, therapy may be required for several weeks. it may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy. table 1. dosing recommendations for adult and pediatric patients > 3 months of age infection severity a usual adult dose usual dose for children > 3 months b ear/nose/throat skin/ skin structure genitourinary tract mild/ moderate 500 mg every 12 hours or 250 mg every 8 hours 25 mg/kg/day in divided doses every 12 hours or 20 mg/kg/day in divided doses every 8 hours severe 875 mg every 12 hours or 500 mg every 8 hours 45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours lower respiratory tract mild/ moderate or severe 875 mg every 12 hours or 500 mg every 8 hours 45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours gonorrhea acute, uncomplicated ano-genital and urethral infections in males and females 3 grams as single oral dose prepubertal children: 50 mg/kg amoxicillin, combined with 25 mg/kg probenecid as a single dose. note: since probenecid is contraindicated in children under 2 years. do not use this regimen in children under 2 years of age. a dosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections. b the children’s dosage is intended for individuals whose weight is less than 40 kg. children weighing 40 kg or more should be dosed according to the adult recommendations. 2.2 dosing in neonates and infants aged ≤ 12 weeks (≤ 3 months) treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. it is recommended that there be at least 10 days’ treatment for any infection caused by streptococcus pyogenes to prevent the occurrence of acute rheumatic fever. due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of amoxicillin 30 mg/kg/day divided every 12 hours. there are currently no dosing recommendations for pediatric patients with impaired renal function. 2.3 dosing for h. pylori infection triple therapy: the recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. dual therapy: the recommended adult oral dose is 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days. please refer to clarithromycin and lansoprazole full prescribing information. 2.4 dosing in renal impairment • patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. • severely impaired patients with a glomerular filtration rate of < 30 ml/min. should not receive a 875-mg dose. • patients with a glomerular filtration rate of 10 to 30 ml/min should receive 500 mg or 250 mg every 12 hours, depending on the severity of the infection. • patients with a glomerular filtration rate less than 10 ml/min should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection. • hemodialysis patients should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection. they should receive an additional dose both during and at the end of dialysis. 2.5 directions for mixing oral suspension tap bottle until all powder flows freely. add approximately 1/3 of the total amount of water for reconstitution (see table 2) and shake vigorously to wet powder. add remainder of the water and again shake vigorously. table 2. amount of water for mixing oral suspension strength bottle size amount of water required for reconstitution oral suspension 125 mg /5 ml 80 ml 66 ml 100 ml 83 ml 150 ml 125 ml oral suspension 200 mg /5 ml 50 ml 39 ml 75 ml 59 ml 100 ml 78 ml oral suspension 250 mg /5 ml 80 ml 59 ml 100 ml 73 ml 150 ml 110 ml oral suspension 400 mg /5 ml 50 ml 34 ml 75 ml 51 ml 100 ml 68 ml after reconstitution, the required amount of suspension should be placed directly on the child’s tongue for swallowing. alternate means of administration are to add the required amount of suspension to formula, milk, fruit juice, water, ginger ale, or cold drinks. these preparations should then be taken immediately. note: shake oral suspension well before using. keep bottle tightly closed. any unused portion of the reconstituted suspension must be discarded after 14 days. refrigeration is preferable, but not required.

st frequently reported adverse events for patients who received triple therapy (amoxicillin/clarithromycin/ lansoprazole) were diarrhea (7%), headache (6%), and taste perversion (5%). dual therapy :the most frequently reported adverse events for patients who received double therapy amoxicillin/lansoprazole were diarrhea (8%) and headache (7%). for more information on adverse reactions with clarithromycin or lansoprazole, refer to the adverse reactions section of their package inserts. 6.2 postmarketing or other experience in addition to adverse events reported from clinical trials, the following events have been identified during postmarketing use of penicillins. because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. these events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to amoxicillin. • infections and infestations: mucocutaneous candidiasis. • gastrointestinal: black hairy tongue, and hemorrhagic/pseudomembranous colitis. onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment [see warnings and precautions (5.2) ] . • hypersensitivity reactions: anaphylaxis [see warnings and precautions (5.1) ] . serum sickness–like reactions, erythematous maculopapular rashes, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and urticaria have been reported. • liver: a moderate rise in ast and/or alt has been noted, but the significance of this finding is unknown. hepatic dysfunction including cholestatic jaundice, hepatic cholestasis and acute cytolytic hepatitis have been reported. • renal: crystalluria has been reported [see overdosage (10) ] . • hemic and lymphatic systems: anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported. these reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. • central nervous system: reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, behavioral changes, and/or dizziness have been reported. • miscellaneous: tooth discoloration (brown, yellow, or gray staining) has been reported. most reports occurred in pediatric patients. discoloration was reduced or eliminated with brushing or dental cleaning in most cases.

anticoagulation. 7.3 allopurinol the concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. it is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients. 7.4 oral contraceptives amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives. 7.5 other antibacterials chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. this has been demonstrated in vitro ; however, the clinical significance of this interaction is notwell documented. 7.6 effects on laboratory tests high urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using clinitest ® (manufactured by miles, inc.), benedict’s solution, or fehling’s solution. since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions [such as clinistix ® (manufactured by bayer corporation)] be used. following administration of ampicillin or amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.

n milk. amoxicillin use by nursing mothers may lead to sensitization of infants. caution should be exercised when amoxicillin is administered to a nursing woman. 8.4 pediatric use because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. dosing of amoxicillin should be modified in pediatric patients 12 weeks or younger (≤ 3 months). [see dosage and administration (2.2) .] 8.5 geriatric use an analysis of clinical studies of amoxicillin was conducted to determine whether subjects aged 65 and over respond differently from younger subjects. these analyses have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. 8.6 dosing in renal impairment amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (gfr <30 ml/min). see dosing in renal impairment (2.4) for specific recommendations in patients with renal impairment.

hr/ml and a c max of 13.8 ± 4.1 mcg/ml. dosing was at the start of a light meal following an overnight fast. orally administered doses of amoxicillin suspension, 125 mg/5 ml and 250 mg/5 ml, result in average peak blood levels 1 to 2 hours after administration in the range of 1.5 mcg/ml to 3 mcg/ml and 3.5 mcg/ml to 5 mcg/ml, respectively. oral administration of single doses of 400 mg chewable tablets and 400 mg/5 ml suspension of amoxicillin to 24 adult volunteers yielded comparable pharmacokinetic data: table 3: mean pharmacokinetic parameters of amoxicillin (400 mg chewable tablets and 400 mg/5 ml suspension) in healthy adults dose* auc 0-∞ (mcg• hr/ml) c max (mcg/ml) † amoxicillin amoxicillin (±s.d.) amoxicillin (±s.d.) 400 mg (5 ml of suspension) 7.1 (3.1)1 5.92 (1.62) 400 mg (1 chewable tablet) 17.9 (2.4) 5.18 (1.64) * administered at the start of a light meal. † mean values of 24 normal volunteers. peak concentrations occurred approximately 1 hour after the dose. distribution : amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. in blood serum, amoxicillin is approximately 20% protein-bound. following a 1gram dose and utilizing a special skin window technique to determine levels of the antibiotic, it was noted that therapeutic levels were found in the interstitial fluid. metabolism and excretion : the half-life of amoxicillin is 61.3 minutes. approximately 60% of an orally administered dose of amoxicillin is excreted in the urine within 6 to 8 hours. detectable serum levels are observed up to 8 hours after an orally administered dose of amoxicillin. since most of the amoxicillin is excreted unchanged in the urine, its excretion can be delayed by concurrent administration of probenecid [see drug interactions (7.1) ]. 12.4 microbiology mechanism of action amoxicillin is similar to penicillin in its bactericidal action against susceptible bacteria during the stage of active multiplication. it acts through the inhibition of cell wall biosynthesis that leads to the death of the bacteria. method of resistance resistance to amoxicillin is mediated primarily through enzymes called beta-lactamases that cleave the beta-lactam ring of amoxicillin, rendering it inactive. amoxicillin has been shown to be active against most isolates of the bacteria listed below, both in vitro and in clinical infections as described in the indications and usage section. gram-positive bacteria gram-negative bacteria enterococcus faecalis staphylococcus spp. streptococcus pneumoniae α and β-hemolytic streptococci. escherichia coli haemophilus influenzae neisseria gonorrhoeae proteus mirabilis helicobacter pylori susceptibility test methods : (susceptibility to amoxicillin can be determined using ampicillin powder and a10 mcg ampicillin disk). when available, clinical microbiology should provide the results of in vitro susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. these reports should aid the physician in selecting an antimicrobial drug product for treatment. dilution techniques: quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (mics). these mics provide estimates of the susceptibility of bacteria to antimicrobial compounds. the mics should be determined using a standardized procedure. standardized procedures are based on dilution methods (broth or agar) 2,3 or equivalent with standardized inoculum concentrations and standardized concentrations of ampicillin powder. the mic values should be interpreted according to the criteria in table 4. diffusion techniques: quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. one such standardized procedure 3 requires the use of standardized inoculum concentrations. this procedure uses paper disks impregnated with 10 mcg ampicillin to test the susceptibility of bacteria to ampicillin. interpretation involves correlation of the diameter obtained in the disk test with the mic for amoxicillin. reports from the laboratory providing results of the standard single-disk susceptibility test with a 10 mcg ampicillin disk should be interpreted according to the criteria listed in table 4. table 4. susceptibility test interpretive criteria for amoxicillin minimum inhibitory concentration (mcg/ml) disk diffuxion (zone diameter in mm) susceptible intermediate resistant susceptible intermediate resistant enterococcu s spp. ≤ 8 - ≥ 16 ≥ 17 - ≤ 16 staphylococcus spp. ≤ 0.25 ≥ 0.5 ≥ 29 ≤ 28 stephylococci, viridians group (α-hemoolytic streptococci ≤ 0.25 -0.5 to 4 ≥ 8 - - - β-hemolytic streptococci ≤ 0.25 - - ≥ 24 - - streptococcus pneumoniae (non-meningitis isolates)* ≤ 2 4 ≥ 8 - - - enterobacteriaceae ≤ 8 16 ≥ 32 ≥ 17 14 to 16 ≤ 13 haemophilus influenzae ≤ 1 2 ≥ 4 ≥ 22 19 to 21 ≤ 18 neisseria gonorrhoeae** - - - - - - *s. pneumoniae should be tested using a 1-mcg oxacillin disk. isolates with oxacillin zone sizes of ≥ 20 mm are susceptible to amoxicillin. an amoxicillin mic should be determined on isolates of s. pneumoniae with oxacillin zone sizes of ≤ 19 mm. **a positive beta lactamase test indicates resistance to amoxicillin. isolates that are resistant to penicillin by mic testing are also expected to be resistant to amoxicillin. a report of “susceptible” indicates the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches concentrations that are usually achievable. a report of “intermediate” indicates that result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. the intermediate category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. the intermediate category also provides a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. a report of “resistant” indicates the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches concentrations that are usually achievable and other therapy(ies) are likely to be preferred. quality control: susceptibility techniques require use of laboratory control microorganisms to control the technical aspects of the laboratory standardized procedures. 2,3,4 standard ampicillin powder should provide the mic values described below. for the diffusion technique using the 10 mcg ampicillin disk, the criteria are provided in table 5. table 5. acceptable quality control ranges for amoxicillin bacteria atcc # mic range (mcg/ml) disk diffusion zone range (mm) escherichia coli 25922 2 to 8 16 to 22 enterococcus faecalis 29212 0.5 to 2 haemophilus influenzae 49247 2 to 8 13 to 21 staphylococcus aureus 29213 0.5 to 2 25923 27 to 35 streptococcus pneumoniae 49619 0.06 to 0.25 # atcc = american type culture collection susceptibility testing for helicobacter pylori : amoxicillin in vitro susceptibility testing methods for determining minimum inhibitory concentrations (mics) and zone sizes have not been standardized, validated, or approved for testing h. pylori . specimens for h. pylori and clarithromycin susceptibility test results should be obtained on isolates from patients who fail triple therapy. if clarithromycin resistance is found, a non-clarithromycin-containing regimen should be used.

ly administered doses of amoxicillin suspension, 125 mg/5 ml and 250 mg/5 ml, result in average peak blood levels 1 to 2 hours after administration in the range of 1.5 mcg/ml to 3 mcg/ml and 3.5 mcg/ml to 5 mcg/ml, respectively. oral administration of single doses of 400 mg chewable tablets and 400 mg/5 ml suspension of amoxicillin to 24 adult volunteers yielded comparable pharmacokinetic data: table 3: mean pharmacokinetic parameters of amoxicillin (400 mg chewable tablets and 400 mg/5 ml suspension) in healthy adults dose* auc 0-∞ (mcg• hr/ml) c max (mcg/ml) † amoxicillin amoxicillin (±s.d.) amoxicillin (±s.d.) 400 mg (5 ml of suspension) 7.1 (3.1)1 5.92 (1.62) 400 mg (1 chewable tablet) 17.9 (2.4) 5.18 (1.64) * administered at the start of a light meal. † mean values of 24 normal volunteers. peak concentrations occurred approximately 1 hour after the dose. distribution : amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. in blood serum, amoxicillin is approximately 20% protein-bound. following a 1gram dose and utilizing a special skin window technique to determine levels of the antibiotic, it was noted that therapeutic levels were found in the interstitial fluid. metabolism and excretion : the half-life of amoxicillin is 61.3 minutes. approximately 60% of an orally administered dose of amoxicillin is excreted in the urine within 6 to 8 hours. detectable serum levels are observed up to 8 hours after an orally administered dose of amoxicillin. since most of the amoxicillin is excreted unchanged in the urine, its excretion can be delayed by concurrent administration of probenecid [see drug interactions (7.1) ].

se assays. in a multi-generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 2 times the 3 g human dose based on body surface area).

ration reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 2 times the 3 g human dose based on body surface area).

re and histology) at 4 to 6 weeks following the end of treatment. triple therapy was shown to be more effective than all possible dual therapy combinations. dual therapy was shown to be more effective than both monotherapies. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. table 6. h. pylori eradication rates when amoxicillin is administered as part of a triple therapy regimen study triple therapy triple therapy evaluate analysis a (95% confidence interval ) (number of patients) intent-o- treat analysis b (95% confidence interval ) (number of patients) study 1 92 [80 - 97.7] (n=48) 86 [73.3 – 93.5] (n=55) study 2 86 [75.7 - 93.6] (n=66) 83 [72 - 90.8] (n=70) a this analysis was based on evaluable patients with confirmed duodenal ulcer (active or within 1 year) and h. pylori infection at baseline defined as at least 2 of 3 positive endoscopic tests from clotest ® , histology, and/or culture. patients were included in the analysis if they completed the study. additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy. b patients were included in the analysis if they had documented h. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within 1 year). all dropouts were included as failures of therapy. table 7. h. pylori eradication rates when amoxicillin is administered as part of a dual therapy regimen study dual therapy dual therapy evaluate analysis a (95% confidence interval ) (number of patients) intent-o- treat analysis b (95% confidence interval ) (number of patients) study 1 77 [62.5 - 87.2] (n=51) 70 [56.8 – 81.2] (n=60) study 2 66 [51.9 - 77.5] (n=58) 61 [48.5 - 72.9] (n=67) a this analysis was based on evaluable patients with confirmed duodenal ulcer (active or within 1 year) and h. pylori infection at baseline defined as at least 2 of 3 positive endoscopic tests from clotest ® , histology, and/or culture. patients were included in the analysis if they completed the study. additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy. b patients were included in the analysis if they had documented h. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within 1 year). all dropouts were included as failures of therapy.

arrhea is a common problem caused by antibiotics, and it usually ends when the antibiotic is discontinued. sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken their last dose of the antibiotic. if this occurs, patients should contact their physician as soon as possible. • patients should be aware that amoxicillin powder for oral suspension contains a penicillin class drug product that can cause allergic reactions in some individuals. distributed by: west-ward pharmaceutical corp. eatontown, nj 07724 usa manufactured by: hikma pharmaceuticals p.o. box 182400 amman 11118 – jordan revised june 2013 relabeled by: proficient rx lp thousand oaks, ca 91320